Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

The possibilities of data-based maintenance management as well as interconnected, smart, and autonomous assets have been discussed lately but in practice there are still a number of major problems regarding e.g. the amount, quality, integration, and exploitation of maintenance data. In LeaD4Value these problems are addressed through lean maintenance data management to realise increased business value. Contrary to the Big Data hype, the idea here is to focus on the data decision support tools to be constructed based on analytical modelling and statistical analyses. Data will be collected from computerized maintenance management systems and enterprise resource planning systems of the two seconded companies, as well as from some of their employees via surveys and interviews. The results include e.g. a map of data exploitation paths, a process model, and a performance measurement system for lean maintenance data management. These tools can be used to reveal unnecessary maintenance tasks and data collection, missing data collection, or potential to increase the business value of maintenance. The role of world-class maintenance is highlighted in European manufacturing, because a majority of new production-related investments are directed to other continents. The proposed work is multidisciplinary by nature, combining aspects of business value management, reliability and maintenance engineering, and data sciences. The multidisciplinary view is needed, for asset management is challenged by maintenance engineers and managers understanding the technical aspects of maintenance but being unable to communicate these to the company decision makers in terms of business value. Too often this leads to short-sighted decisions. The project will expand the competences of the fellow in multiple disciplines, and provides international experience in science and business.

Advances in fit for use manufacturing of biopharmaceutical drug delivery and pharmaceutical systems are now required to fit Quality by Design (QbD) models. These current regulations require excellence to be built into the preparation of emerging products (both material and process) thereby leading to product robustness and quality. In addition, industrial needs (economical and reproducible quality enhancement) are driving manufacturing towards continuous processes over batch type processes which also rely on QbD (for integrity and quality). EHDA technology is a robust process that has been utilised in various formats (e.g. electrospinning, electrospraying, bubbling and even 3D printing) and is favourable due to applicability with the development of stable nanomedicines and biopharmaceuticals, the emergence of this technology is clearly evident in the UK and on the global scale. Attempts in scaling up (for suitable pharmaceutical scale) and in tandem with continuous processes (including controlled manufacturing) have been very limited. There also, now, remains a huge void in the adaptation of sensible QbD (multi-variate) for the current methods developed and also those required by industry. While lab scale research continues with the ongoing development of such processes (e.g. nanomedicines, smart and controlled delivery), the transition to industry or the clinic will have to meet these regulations (and scales) for there to be a real impact, which is now, also, an important aspect of grass root research in the UK. The EHDA network brings together specialists from academia and industry to advance this technology through several means. Firstly, initiating developments towards a real-viable scale for Pharmaceutical production. Secondly, to incorporate developments in lean manufacturing and legislation (e.g. continuous manufacturing, online diagnostics, QbD and adaptable scale). Thirdly, to marry optimised lean technologies with novel and emerging macromolecular therapies and actives. The network has a wide range of activities and initiatives which will lead to significant developments (and collaborations) in an area of increasing global interest (EHDA processes) - but currently only on a viable lab scale to date. This network will be the first of its kind and will serve as the central and pioneering hub in this remit.

Between 1918 and 1983 West Belfast went from being the weakest Sinn Fein constituency in Catholic Ireland to the strongest. How this happened is explained through the first biography of the Parliamentary Nationalist leader Joe Devlin (1871-1934), set in the context of his local Catholic community. In the 1921 partition Belfast's Nationalist were double-losers, to Sinn Fein and to Ulster Unionism. In the communal memory of republicans and southerners Devlin's moderation and his sectarian jobbery were to blame. This research presents Devlin in a more favourable light, and suggests a more critical approach to the policies of revolutionary Sinn Fein.